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I.! Bibliographic!Summary!!Krasselt,!Marco!Lothar!!CD56+! Monocytes! Have! a! Dysregulated! Cytokine! Response! to! LPS! and!Accumulate!in!Rheumatoid!Arthritis!and!Immunosenescence!!Universität!Leipzig,!Dissertation!38!S.,!150!Lit.,!3!Abb.,!1!Tab.,!5!Anlagen!!Monocytes!are!no!longer!regarded!as!a!homogenous!cell!population!but!can!be!divided,!both!phenotypically! and! functionally,! into! different! subsets.! In! rheumatoid! arthritis,! the!subpopulation!of!CD14bright/CD16+!monocytes!is!expanded!and!prone!towards!generation!of!Th17!cells.!CD56+!monocytes!represent!a!different!subpopulation,!which!is!also!expanded!in!conditions!associated!with!autoimmunity! like! inflammatory!bowel!diseases.!The!aim!of!the!study!was!the!quantification!and!functional!characterization!of!the!CD56+!monocyte!subset!in!rheumatoid!arthritis!(RA).!The!work! at! hand! shows! that! the! frequency! of! CD56+!monocytes! is! also! expanded! in! RA;!moreover,! this! subpopulation! seems! to! increase! with! age! in! healthy! controls.! This! age!association!is!completely!lost!in!patients!suffering!from!RA.!!Further! functional! investigations! could! demonstrate! a! dysregulated! cytokine! response! to!lipopolysaccharide! (LPS)!with! an! increased!production! of! proFinflammatory! cytokines! like!TNFα!as!well!as!an!increased!spontaneous!reactive!oxygen!intermediate!(ROI)!production.!A!longitudinal! treatment! study! using! Etanercept! as! an! established! TNFαFblocking! agent!revealed! a! decrease! of! the! frequency! of! that! cell! population! under! therapy.! This! decrease!was!more!pronounced!in!patients!with!a!good!treatment!response!as!judged!by!the!reduction!of!the!disease!activity!score!(DAS)!28.!Summing! up! those! results,! the! CD56+! monocyte! subset! might! be! involved! in!immunosenescence!as!well!as!in!the!pathogenesis!of!RA.!
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II.! Introduction!!Rheumatoid! Arthritis! (RA)! is! an! inflammatory,! autoimmune! disease!which! has! a! systemic!character:!being!the!most!common!form!of!inflammatory!arthritis,!it!is!not!only!affecting!the!human!body’s!joints,!but!can!also!lead!to!a!variety!of!extraFarticular!manifestations.!Though!patients!are!typically!suffering!from!symmetrical!joint!pain!and!swelling,!symptoms!can!also!include!systemic!disease!manifestations! like! fatigue!and!chronic!disease’s!anemia,!but!also!severe!problems,!e.g.!serositis,!vasculitis!or!even!interstitial!lung!disease.!Rheumatoid!Arthritis! is! a! common!disease!with! an! incidence!of! approx.! 41!new!cases!per!100.000! people! a! year! [1]! and! a! prevalence! of! 0.5F1! %! [2]! in! the! general! population.!Incidence!appears!to!be!rising!with!age!and!peaks!among!people!aged!around!70!with!rates!up!to!89!per!100.000.! !The! lifetime!risk!of!developing!RA!was!estimated!3.6!%!for!women!and!1.7!%!for!men,!respectively![3].!The!clinical!presentation!of!RA!has!changed!during!the!last!two!decades.!Crippling!arthritis!is!seen!less!often,!while!an!early!diagnosis!due!to!improved!diagnostic!tools!has!become!much!more! common! during! the! last! years.! This! is! not! only! due! to! the! more! specific! antiFcitrullinated!proteins/peptides!antibodies!(ACPA)!used!to!detect!the!disease,!but!also!due!to!the!recently!changed!ACR/EULAR!criteria!of!RA!allowing!diagnosing!the!disease!in!an!early!stage.! These! improvements! are! accompanied! by! the! early! induction! of! a! sequential! antiFinflammatory!therapy!with!a!greater!variety!of!potent!drugs.!It!is!important!to!mention!the!TNFα! inhibitors! here,! the! development! of! which! was! a! huge! step! forward! in! treating! RA!successfully.!Despite! all! those! clinical! improvements,! deciphering! the! pathogenesis! of! Rheumatoid!Arthritis!is!still!challenging!and!further!research!is!clearly!required.!On!the!one!hand,!there!are! the! underlying! mechanisms;! on! the! other! hand! there! is! a! disturbed! panel! of! effector!cytokines.!It!is!very!important!to!distinguish!between!those!two!points:!Influencing!the!levels!of!inflammatory!cytokines!such!as!TNFα!due!to!(receptorF)blocking!agents!is!one!approved!clinical!way!to!treat!the!disease!successfully.!Why!these!levels!are!elevated!is!a!question!still!not!satisfactorily!answered!yet.!Similarly,!why!TNF!inhibitors!help!some!patients!while!they!totally!fail!in!others!remains!a!mystery.!A!lot!of!research!work!today!is!concentrated!on!the!effector!mechanisms,!finding!new!targets!or!new!agents!to!known!targets.!
II.&1&Genetics&of&Rheumatoid&Arthritis&The!pathogenesis!of!RA!seems!to!have!multiple!aspects.!Beneath!wellFknown!environmental!risk! factors! for!developing!an!RA!there!are!genetic!alterations! increasing! the!susceptibility!for! the!disease,!especially! for! the!seropositive!variant.!First!hints! for! the!heritability!of!RA!were! found!due! to! epidemiologic! studies,! followed!by! the! comparison!of!homozygotic! and!dizygotic!twins,!where!a!concordance!for!RA!of!15.4!%!for!monozygotic!but!only!3.6!%!for!
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dizygotic! twins!was! shown! [4,5].!Overall,! genetic! factors! seem! to!be! responsible! for! about!60!%!of!RA’s!distribution!within!a!population,!regarding!to!quantitative!genetic!studies![6].!
II.1.1$ Shared$Epitope$When!it!comes!to!genetics!and!RA,!it!is!important!to!have!a!closer!look!on!the!HLA!(Human!Leukocyte!Antigen)FDRB1!locus!and!the!“shared!epitope”.!Studies!showed!HLAFDRB1!being!responsible!for!about!one!third!of!the!genetic!contribution!towards!RA![7].!The!term!!“shared!epitope”!is!used!for!a!set!of!HLAFDRB1!alleles,!all!of!which!are!coding!for!four!amino!acids!in!the! 3rd! hypervariable! region! of! the! DRβ! chain! belonging! to! the! Major! Histocompatibility!Complex! (MHC)! class! II!which! form! the! actual! antigen! binding! site! [8].! Depending! on! the!individual!HLAFDRB1!shared!epitope!susceptibility!alleles,!the!risk!of!developing!RA!differs:!the!DRB1*0401!allele!goes!along!with!a! relative! risk! (RR)!of! about!3,!while!DRB1*0101! is!proposed!to!have!a!RR!of!1.5.!The!alleles!seem!to!be!very!stable!within!a!population,!most!commonly!found!throughout!Europe!are!the!alleles!*0101,!*0401!and!*0404!(f!>!5!%)!while!*0405! and! *0901! are! the! most! common! ones! in! Asia.! Despite! these! findings,! the! shared!epitope! is! associated! with! RA! in! different! populations,! regardless! of! which! alleles! are!predominantly! found![9].!Furthermore,!more!recent!works!could!show!that!distinct!shared!epitopesFpositive! alleles! do! not! only! increase! the! risk! of! developing! an! RA,! but! are! also!connected! to! the! disease’s! severity! in! terms! of! radiologic! joint! destruction! (HLAFDRB1!*0401/*0401,! *0401/*0404,! *0404/*0404!and! *0401/x)! and!developing! an! accompanying!rheumatoid! vasculitis! (HLAFDRB1! *0401/*0401,! *0401/*0404! and! *0101/*0401)! [10,11].!As! illustrated! by! these! findings,! this! association! is! strongly! doseFdependent,! usually! being!higher!in!homozygous!or!compound!heterozygous!individuals.!
II.1.2$ Other$Genetic$Causes$Other! risk! genes! seem! to! be! less! important! with! a! lower! RR! and,! moreover,! ethnicity!dependent.!The!PTPN22!gene!polymorphism,!for!example,!has!been!shown!to!be!associated!with! RA! in!Western! countries,! including! Europe! and! the! US! [12F14].! Studies! estimated! a!frequency!of!about!10!%!within!the!population!for!Northern!America![13,15,16].!In!contrary,!in!Asians,! the!polymorphism!was!not!even! found!at!all! [16].!The!actual!polymorphism! is!a!single! nucleotide! polymorphism! (SNP)! and! leads! to! a! gain! of! function! of! the! tyrosine!phosphatase!the!PTPN22!gene!is!coding!for.!This!enzyme!is!involved!in!the!termination!of!T!cell! receptor!(TCR)!signaling,! thereby!establishing!a!negative! feedback!regulation,!which! is!more!active! in! individuals!carrying!this!polymorphism.!Taking!the!mechanism!of!the!coded!protein! and! its! enhancement! into! consideration,! one! would! not! primarily! think! of! its!involvement! in! an! autoimmune! disease,! and! particularly! not! in! peripheral! T! cells.! It! has!therefore! been! proposed! that! the! polymorphism! especially! affects! the! thymic! T! cells,!resulting! in! a! compromised! negative! selection! of! autoreactive! cells! [17,18].!The! described!mechanism!could!consequently!lead!to!an!autoimmune!disease!and!is!not!exclusive!for!RA;!further! studies! also! found! an! association! of! the! PTPN22! polymorphism! with! other!autoimmune! diseases,! namely! Graves’! disease,! type! 1! diabetes! mellitus,! vitiligo,! systemic!lupus!erythematodes!and!juvenile!idiopathic!arthritis![19].!
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Today,! there! is!a! total!of!31!RA!risk! loci!known,! including!STAT4,!CD40,!CTLA4!and!CCR6,!just!to!name!a!few![20].!Based!on!our!current!knowledge,!they!seem!to!contribute!little!to!the!RR!of!actually!developing!the!disease,!and!therefore!to!the!genetic!predisposition.!The!major!players!here!are!the!SE!and!PRPN22;!they!contribute!for!about!50!%!of!the!genetic!disease!susceptibility![21].!
II.2& Antibodies&In!autoimmune!diseases,!it!is!hypothesised,!that!the!body’s!own!immune!system!is!reacting!against! the!body’s!very!own!tissues;! in! terms!of!RA,! the! targets!appears! to!be! the!synovial!membrane,!and!probably!some!extraFarticular!tissues!and!structures.!Unfortunately,!RA!does!not! seem! to! be! a! typical! autoimmune! disease.! Autoantibodies! used! for! diagnosing! RA! are!Rheumatoid!factors!(RF),!as!well!as!antiFcitrullinated!proteins/peptides!antibodies!(ACPA).!Surprisingly,!both!of!them!are!directed!against!antigens!widely!distributed!also!outside!the!joint.! RF! are! autoantibodies! against! the! Fc! fragment! of! Immunoglobulin! G! (IgG)! and! have!been!known! for! almost! 90! years.! Their! specificity! for!RA! is! low! (approx.! 79!%),! they! also!occur! in!other!diseases!or! inflammatory!conditions,!e.g.! Sjögren’s!Syndrome!or!Hepatitis!C![22,23].! The! more! specific! ACPA! (specifity! approx.! 95! %)! [22,24]! are! directed! against!proteins! in!which! an! amino! acid! residue! has! been! converted! from! arginine! to! citrullin! by!deamination,! catalysed! by! the! peptidylarginine! deiminase! (PADI).! This! posttranslational!alteration!leads!to!a!different!threeFdimensional!structure!of!the!affected!protein!and!takes!place!in!many!tissues!all!over!the!body![25].!The!most!important!“citrullinated”!proteins!in!this! context!are!matrix!proteins! such!as!vimentin,! fibrinogen,!keratin!and! fillagrin.!Altered!vimentin!is!even!found!in!the!rheumatoid!pannus!inside!the!joint![26,27].!Since! it!has!such!an! important! role! in!creating!antigens!und!subsequently!ACPA,! it!was!an!almost! imperative! assumption! to! look! for! an! association! between! the! PADI! and! RA.!Interestingly,! a! polymorphism!within! PADI4! seems! to! be! associated!with! RA! in! the! Asian!population! [28F30].! No! such! association! could! be! demonstrated! for! Caucasians! though,!emphasizing!the!presumed!differences!of!RA’s!pathogenesis!depending!on!ethnicity!(see!also!
PTPN22!in!II.1.2)![31F33].!!The! role! of! autoantibodies! in! the! pathogenesis! of! RA! is! not! fully! understood! yet.! Several!studies! show! that! ACPA! can! be! detected! very! early,! even! a! long! time! before! a! clinical!manifestation!of!the!disease![34].!ACPA!are!superior!to!RF!not!only!in!detecting!the!disease,!but!also!as!prognostic!indicators!of!disease!activity!and!joint!destruction.!Both,!ACPA!and!RF,!indicate!a!poorer!radiologic!outcome!and!a!higher!disease!activity!independently![35,36].!Of!!RF! negative! patients,! approx.! 20! %! are! positive! for! ACPA,! while! approx.! 15F20! %! of! RA!patients!only!test!positive!for!RF!without!having!ACPA.!About!one!third!of!all!RA!patients!are!negative!for!both!autoantibodies.!The!highest!sensitivity!and!specificity!is!therefore!reached!when!testing!for!both,!ACPA!and!RF!with!a!positive!predictive!value!of!almost!100!%![37].!Thus,! autoantibodies! are! used! to! detect! RA! and,! moreover,! to! predict! the! severity! of! the!disease.! They! seem! to! be! pathognomonic,! which! is! especially! true! for! ACPA,! which! are!
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directed!against!altered!matrix!molecules!as!described!above.!There!is!also!a!link!to!the!HLA!alleles! and! their! distinct! SE:! recent! studies! came! to! the! conclusion,! that! HLA! alleles! are!rather!associated!with!RF!and!antiFcitrullinated!peptide!antibody!production,!than!with!RA!itself![36,38,39].!Despite!all!those!findings,!there!is!still!the!riddle!of!the!clinically!identical,!but!serologically!RF!and!ACPA!negative!RA.!The!existence!of! this!“seronegative”!disease!variant! leads!to!the!assumption,!that!even!the!most!specific!autoantibody!is!either!not!necessarily!involved!in!the!pathogenesis!of!the!disease!itself,!or!that!RA!is!not!a!homogenous!disease!entity.!
II.3& Environmental&Factors&Smoking! is! thought! to! be! the! most! important! and! bestFexamined! external! risk! factor.!Depending!on! the! smoking!duration!and! the!daily!dose,! a!RR!of!up! to!3.0!was! found! [40].!Both,!tobacco!dose!and!smoking!years!seem!to!increase!the!risk!dramatically.!Interestingly,!again! a! strong! association! with! a! positive! status! for! ACPA! was! found! [40,41].! Moreover,!smoking! seems! to! increase! the! risk! for! developing! seropositive! RA! in! a! multiplicative!manner,! especially! in! the! presence! of! other! (“internal”)! risk! factors,! such! as! HLA! SE! or!PTPN22![42].!One!proposed!explanation! is!an! increased!peptide!deamination/citrullination!in! smokers! in! the! presence! of! HLA! SE.! However,! results! from! different! authors! remain!conflicting,!with!some!being!unable!to!reproduce!the!HLA!SE/smoking!association![41,43,44].!
II.4& Adaptive&Immunity&Major!players!of!the!adaptive!immunity!are!the!T!cells.!First!of!all,!they!can!be!divided!into!helper!(CD4+)!and!cytotoxic!(CD8+)!T!cells.!Both!of!them!are!found!in!the!synovial!membrane,!where!T!cells!are!the!greatest!cell!population,!accounting!for!up!to!50!%!of!all!cells![45].!That!is! one! of! the! reasons,! why! T! cells! have! been! thought! to! be! involved! in! RA! pathogenesis!throughout!the!last!3!decades.!Another!one!is!the!fact,!that!experimentally!induced!arthritis!could!be!transferred!by!using!T!cells!alone,!especially!CD4+!ones![46F48].!The! CD4+! T! helper! cells! themselves! can! be! further! divided! both! functionally! and!phenotypically! into! four! different! subsets:! Th1,! Th2,! Th17! (effector! T! cells)! and! Tregs!(regulatory! T! cells).! In! terms! of! RA,! the! Th1! subset! and! the! Tregs,! as! well! as! the! more!recently!discovered!Th17!subset,!are!probably!of!greatest!importance.!
II.4.1$ Th1$Cells$The!Th1!cells!are!characterized!by!a!distinct!cytokine!pattern!and!mechanism!of!action.!Their!signature!cytokine! is! IFNγ,! separating! them! from!the!Th2!subset!especially!producing! ILF4!and! ILF13.! For! a! long! time,! RA! was! thought! to! be! a! Th1! disease,! arising! from! the! rather!proinflammatory! phenotype! of! that! T! cellFsubset.! The! results! in! studies! of! experimental!arthritis!and!IFNγ!have!been!conflicting!though,!questioning!the!role!of!Th1!cells!in!RA![49],!especially!with!regards!to!the!more!recently!discovered!Th17!subset.!
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II.4.2$ Th17$Cells$The! characterization! of! the! Th17! subset! was! a! huge! step! forward! in! understanding!autoimmune! diseases,! and! describes! a! cell! population! named! after! their! predominantly!produced!cytokine!(ILF17A),!which!in!itself!is!able!to!induce!inflammation,!angiogenesis!and!cartilage/bone! breakdown! [50,51].! Th17! cells! are! recognized! as! a! distinct! subset,!differentiating! from! naïve! precursors! within! an! environment! containing! ILF6,! ILF23! and!TGFβ![51,52].!Studies!could!show!that!they!are!associated!with!RA,!finding!increased!ILF17!levels!within!both,!blood!and!synovial!membrane!of!the!patient.!Furthermore,!there!seems!to!be! a! correlation! between! RAFinduced! joint! damage! and! those! cytokine! levels! [53,54].!Just!recently,! our!group!was!able! to! find!a! link!between! the!adaptive!and! the! innate! immunity!right! here:! the! Th17! differentiation! is! (also)! being! induced! by! a! distinct!monocyte! subset!(CD14brightCD16+)!in!culture.!This!subset!is!also!occuring!in!increased!frequencies!within!the!peripheral!blood!of!RA!patients,!and!correlates!with!the!ex!vivo!measured!Th17!cell!amount![55].!!
II.4.3$ Tregs$Tregs!are!“Regulatory”!T!cells,!which!are!responsible!for!suppression!of!effector!T!cells!like!Th1,!Th2!and!Th17;!they!are!therefore!thought!to!“regulate”!the!adaptive!T!cellFresponse!and!also! to! prevent! autoimmunity! by! establishing! selfFtolerance! [56].! Interestingly,! several!studies!could!show!them!to!be!present! in! the! rheumatoid!synovium! in! increased!numbers![57].!Although!they!are!supposed!to!suppress!T!cell!activity!there,!they!seem!to!be!unable!to!do! so.! This! notion! is! supported! by! the! finding,! that! Tregs! in! RA! patients! might! have! a!decreased! potential! to! downregulate! TNFα! and! InterferonFγ! production! by! T! cells! and!monocytes! [58,59].! Moreover,! TNFα! as! a! main! player! and! pharmacological! target! in! the!treatment!of!RA!is!found!abundantly!within!patient’s!joints!and!seems!to!suppress!the!Tregs’!function! itself! by! decreasing! FoxP3! expression.! The! importance! of! this! mechanism! is!underlined!by!the!observation,!that!antiFTNFα!therapy!using!Infliximab!leads!to!an!increased!amount! of! Tregs! with! an! increased! FoxP3! expression,! restoring! the! cytokineFsuppressive!Treg!function![59].!
II.4.4$ B$Cells$B!cells!are! the!second! large!population!of! lymphocytes! in! the!rheumatoid!synovium.!Their!interaction! with! T! cells! is! required! for! an! adequate! immune! response! in! healthy! human!beings! due! to! antigen! presentation! (=activation)! and! signal! amplification! by! positive!feedback! stimulation.! This! twoFdirectional! interaction! and! the! finding! of! RAFspecific!autoantibodies!implicate!their!involvement!in!the!complicated!pathogenesis!of!RA.!Moreover,!germinal!centreFlike!structures,!which!are!a!histological!hallmark!of!the!disease,!can!only!be!found!in!the!synovial!membrane!of!RA!patients!in!which!dividing!B!cells!are!also!present![60].!Besides! this! finding,!B! cells! are! able! to!produce! antibodies! even!without!T! cell! “help”:! the!ligation!of!both,!the!B!cell!receptor!(BCR)!and!the!TollFlike!receptor!(TLR)!9!are!sufficient!for!B! cell! activation! and! antibody! production.! This! mechanism! was! shown! to! lead! to! RF!
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production!in!experimental!arthritis![61].!!B!cells!producing!RF!seem!to!be!able!to!get!help!from!nonFautoreactive!T!cells!(i.e.!T!cells!not!responsive! to! IgG/IgM)! by! presenting! foreign! antigens! using! the! RFFspecific! BCR! [62].!Physiologically,!at!this!point!there!ought!to!be!a!failsafe!mechanism,!leading!to!a!reduced!life!span!of!autoreactive!B!cells!and!preventing!class!switching.!In!short,!it!is!thought!that!B!cells!specific!for!a!soluble!antigen!should!receive!a!negative!signal!due!to!the!missing!complexes,!leading! to!apoptosis.!The!soluble!RF,!on! the!contrary,! is! able! to! selfFpolymerize!within! the!follical! centre,! forming! immune! complexes! and! therefore! aquiring! C3d,! subsequently!resulting! in! a! positive! feedbackFsignal! to! parent! B! cells! due! to! extensive! activation! of! the!specific!Complement! receptor! (CR)!2! [63].!Summing!up! those! findings,! immune!complexes!can! be! a! positive! signal,! leading! to! “selfFperpetuating”! B! cells! being! involved! in! the!pathogenesis!of!RA![64].!Reducing!those!B!cell!clones!is!one!principle!of!today’s!RA!therapy!by!using!the!chimeric!IgG1!CD20Fantibody!Rituximab.!
II.5& Innate&Immunity&Monocytes!are!an!important!subset!of!the!human!peripheral!white!blood!cells!and!F!besides!the!polymorphonuclear!neutrophils!(PMN)!F!one!of!the!inate‘s!immune!system!main!actors.!They! are! responsible! for! phagocytosing! and! destroying! infectious! agents! and! pathogens.!While! they! are! less! effective! against! bacteria! than!PMNs,! they! are! actually! able! to!present!phagocytosed!and!processed!antigens!to!other!immune!cells!like!T!cells!and!belong!therefore!to!the!soFcalled!Antigen!Presenting!Cells!(APCs).!Taking!this! into!consideration,!monocytes!are!basically! inflammatory! immune!cells! in! the! first! line!of!defense,! and!provide!–! in! their!role!as!APCs!–!a!link!to!the!adaptive!immune!system.!Besides!these!important!functions!they!can!also!cause!severe!damage!in!the!tissue!due!to!both,!cytokine!production!(ILF1β,!ILF6!and!TNFα)! leading! to! T! cell! activation/Fattraction! on! the! one! hand! and! different! enzymatic!systems! (collagenases,! enzymes! like! NADPHFoxidase! generating! Reactive! Oxygen!Intermediates![ROI])!on!the!other!hand![65].!Their! role! in! the! pathogenesis! of! RA! is! yet! not! fully! understood,! but! according! to! the!literature,! they! seem! to! be! especially! important! after! differentiation! into!macrophages.! In!this! form! they! are! able! to! migrate! to! the! synovial! membrane,! where! they! are! found! in!increased! frequencies! and! are! considered! to! take! part! in! the! typical! tissue! damage! in!patients!suffering!from!RA!after!getting!activated!by!cytokines,!T!cells!or!receptors!like!the!TLR.! Radiologic! articular! destruction! seems! to! be! correlated! with! the! amount! of! tissue!infiltration!by!macrophages![66,67].!Moreover,!most! inflammatory!cytokines,!which!are! important! in!RA!and!which!decrease! in!response! to! conventional! therapy!using! antiFinflammatory!drugs! as!well! as! directly! acting!antiFcytokine! therapies! are! mainly! produced! by! macrophages.! This! is! especially! true! for!TNFα,!making!macrophages/monocytes!the!major!mediator!of!inflammation,!even!if!T!cells!might!trigger!the!initial!disease!process![65,68,69].!AntiFcytokine!therapy!is!therefore!also!an!antiFmonocyte!therapy.!This!assumption!is!emphasized!by!the!recent!findings!about!reverse!
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signaling! through! the! transmembrane! TNF:! as! our! group! was! able! to! show,! InfliximabFligation! of! tmTNF! on! monocytes! leads! to! inhibition! of! the! constitutive! NFFκB! activation,!suppresses! spontaneous! ILF1β! production! and! induces! apoptosis! within!monocytes! in! RA!patients!but!not!in!healthy!controls![70].!Peripheral!monocytes! can!be! further!divided! into! three!populations!by!using! their! surface!markers!CD16!(Fcγ!receptor)!and!CD14!(TLR!4)![71,72].!A!missing!expression!of!CD16!and!a!high!level!of!CD14!(CD14bright/CD16F)!characterize!the!major!one!(about!85F90!%),!followed!by!CD14+/CD16+!cells!(8!%)!and!the!smallest!population,!CD14bright/CD16+!(4F5!%).!This!last!subpopulation!seems!to!be!connected!to!RA!as!described!in!the!Th17!section!of!this!thesis.!It!is! already! known! that! the! monocyte! compartment! is! disturbed! in! patients! with! RA![55,73,74].!More! recently,! a! separate! and! less! wellFcharacterized! monocyte! subpopulation! has! been!described!which!is!characterized!by!the!expression!of!the!surface!marker!CD56![75].!CD56+!monocytes! are! found! in! low! frequencies! in! the! peripheral! blood! of! healthy! individuals![75,76],! patients! with! Down! syndrome! [77]! and! patients! with! chronic! myelomonocytic!leukemia![78].!This!monocyte!subpopulation!is!expanded!in!Crohn’s!disease![76],!produces!typical!monocyte! cytokines!and! is! a!more!efficient!antigenFpresenting! cell!population!with!regard!to!the!induction!of!a!TFcell!alloresponse![75].!The!surface!molecule!CD56!is!an!isotype!of!the!Neural!Cell!Adhesion!Molecule!(NCAM)![79]!and!usually!a!typical!natural!killer!(NK)!cell!marker![80,81],!but!is!also!found!on!some!T!cells![82,83].! However,! it! has! initially! been! described! on! neurons! where! it! is! thought! to! be!important!in!cell!adhesion!and!to!enhance!the!cellFtoFcell!contact![84F87].!Such!an!adhesive!function!has!also!been!suggested!for!NK!cells!where!it!is!thought!to!be!involved!in!effectorFtarget!cellFinteraction!by!homophilic!bindings!between!the!NKC!and! its! target! [88,89].!The!function!of!this!new!monocyte!subpopulation!is!not!yet!revealed,!but!it!is!suggested!to!have!regulatory!tasks!in!cytotoxity!and!might!promote!Th1Ftype!γδ!TFcell!responses![90].!
II.6& Immunosenescence&The! incidence! rates! of! many! diseases! increase! with! advancing! age,! e.g.! cancer,! severe!infections!or!autoimmune!diseases!like!RA.!It!is!believed!that!this!could!be!explained!by!the!ageFassociated! alterations! of! the! immune! system,! termed! Immunosenescence! [91F93].! The!investigation!of!this!phenomenon!has!been!one!of!the!main!fields!of!immunologic!research!in!the!last!years.!!Particularly!well!examined,!especially!in!terms!of!RA,!is!the!adaptive!immune!system!with!its!main!players,! the!T! cells.!The! results!obtained! so! far! for! the! innate! system!are! conflicting,!arising!from!investigations!on!blood!cells!in!different!states!of!development!(i.e.!monocyte!vs.!macrophage)!and!often!from!animal!samples:!lots!of!the!studies!concentrate!on!rodents![94F97].! Taking! this! into! consideration,! it! is! not! surprising! that,! for! example,! the! cytokine!secretion! of! cells! from! elderly!was! found! to! be! increased! both! in! human! [98F100]! and! in!murine! cells! [101,102].! This! conflict! is! complicated! even! further! by! the! fact! that!many! of!
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those! results! are! obtained! from! in! vitro! experiments,! while! only! few! in! vivo! studies!were!performed.! Similar! conflicts! were! found! for! chemotactic! and! phagocytotic! capacity! of!monocytes!as!well,!with!some!studies!detecting!no!ageFrelated!effects!at!all![103F105].!!However,! widely! accepted! and! approved! is! a! condition! called! inflameFaging,! describing! a!chronic! proFinflammatory! status! in! the! elderly! [106,107]! probably! characterized! by! a!progressive!increase!of!cytokines!in!serum,!especially!ILF6!with!measurements!up!to!ten!fold!compared! to! younger! subjects! [108F110].! Taking! all! the! described! findings! into!consideration,! the! assumption! of! an! increased! cytokine! production! in! elderly! seems! to! be!established!most!firmly!and!conclusively.!!When! thinking! of! inflammation,! reactive! oxygen! intermediates! (ROI)! must! be!mentioned.!One!of!the!first!and!most!accepted!findings!about!aging!in!general!was!the!assumption!of!free!radicals!being!involved!in!the!aging!process!more!than!half!a!century!ago![111].!Depending!on!their!stage,!monocytes!are!able!to!produce!large!amounts!of!ROIs.!There!is!also!consensus!about! a! connection! between! the! pathogenesis! of! RA! and! immunosenescence,! especially! of!the! adaptive! immune! system! [112,113].! RA! is! probably! not! caused! by! a! fully! competent!immune! system! with! autoreactive! cells! that! have! not! been! eliminated! by! tolerance!mechanisms.! Rather,! it! appears! to! be! caused! by! a! prematurely! senescent! immune! system!with!different!ageFrelated!alterations!like!the!reduction!of!the!absolute!amount!of!T!cells!and!their! diversity,! loss! of! CD28! expression! and! ageFinappropriate! telomere! shortening! [113F115].!These!changes!are!probably!leading!to!autoreactive!T!cells!independent!of!the!pivotal!CD28! coFstimulation.!Besides! these! findings,! other! investigations! could! also! show! that! age!affects!the!Th1!and!Th2Fdifferentiation!of!CD4+!cells!in!mice!negatively,!interestingly!without!affecting!Th17Fdifferentiation.!Moreover,!the!Th17!cells!from!elderly!people!seem!to!produce!more! ILF17! [116,117].! !More! recent! investigations! on! rodents! brought! rather! conflicting!results!with! an! increased!proportion!of!Th17! cells! (naïve! and!memory! cells)! in! aged!mice![118].! On! the! other! hand! though,! a! current! study! in! humans! shows! an! increased!differentiation! of! ILF17! effector! cells! from! naïve! CD4+! lymphocytes! in! the! elderly! with! a!decreased!frequency!of!ILF17Fproducing!cells!within!the!memory!T!cell!compartment![119].!Very! recently,!other! investigators!even! found!a! reciprocal! relationship!between!Th17!cells!and!Tregs! throughout! a! human’s! life!with! an! imbalance! towards!Th17!when!getting!older![120].! Summing!up! these! results,! they!clearly!provide!support! for! the!assumption!of!Th17!cells!being!involved!in!immunosenscence!and!probably!even!in!the!pathogenesis!of!RA.!
II.7& Considerations&for&the&Study&Presented&and&the&Aims&Pursued&As! shown! on! the! previous! pages,! the! pathogenesis! of! RA! is! complicated! and! only! partly!understood!to!date.!Circulating!antibodies!play!a!pathogenic!role,!as!do!different!players!of!the!adaptive!and!innate!immune!system.!Epidemiology!shows!us!that!RA!is!a!disease!of!older!patient,! similar! to! different! kinds! of! cancer,! arteriosclerosis! and! some! severe! infections.!Already! this! fact! alone! implies! the! described! changes! of! the! immune! system! termed!immunosenescence! in! the! pathogenesis! of! RA! as! an! autoimmune! disease.! Further!
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implications!came!from!investigations!like!the!description!of!the!Th17!subset!with!the!ageFdependent!changes!of!that!population,!their!possible!link!to!a!monocyte!subset,!the!severely!altered! T! cell! department! and! the! “inflameFaging”! condition! with! increased! cytokine!secretion!mainly! produced! by!mononuclear! cells.! It! appears! that! both! arms! of! the! human!immune!system!are!altered!and!probably!involved!in!RA.!After! reading! the! work! of! Grip! et! al.,! showing! a! connection! between! a! monocyte!subpopulation! and! another! inflammatory! disease! responsive! to! TNFα! blocking! agents!(Crohn’s),! the! idea! of!measuring! the! frequency! of! CD56+!monocytes! as! cells! of! the! innate!immunity! in! RA! patients! and! healthy! controls! was! born.! In! the! initial! analyses,! the!correlation! of! the! CD14bright/CD56+! cell! frequencies! in! healthy! control! with! their! age! was!readily!detectable,!which!encouraged!us!to!further!investigate!this!subpopulation,!especially!in! view! of! the! lack! of! an! ageFrelated! correlation! in! the! overall! patients! group.! We!hypothesized,!that!a!connection!of!those!findings!with!immunosenescence!might!exist,!which!prompted!us!to!characterize!those!cells!further.!The!possible!link!was!moreover!emphasized!by!the!fact!that!young!RA!patients!around!their!thirties!seem!to!have!more!CD56+!monocytes!than! ageFmatched! healthy! donors.! Both! groups,! RA! patients! and! healthy! controls,! were!therefore!expanded!and!functional!investigations!were!performed!to!investigate!the!function!of!this!monocyte!subset.!The! next! step!was! a! small! longitudinal! therapy! study! using! Etanercept,! a! chimeric! fusion!protein! consisting! of! the! Fc! fragment! of! IgG1! and! the! soluble! human! TNF! receptor! 2!(TNFR2),!capable!of!binding!and!“inactivating”!TNFα.!Aim!of!the!study!was!to!investigate!a!potential! influence! of! the! TNFFblocking! therapy! on! the! amount! of! CD56+! monocytes,! in!correlation!with!disease!symptoms!in!patients!suffering!from!RA.!The!patients!for!this!study!were!recruited! from!the!outpatient!clinic!within!our!Rheumatology!unit.!The!results!of! the!investigations!mentioned! above!were! published! and! are! further! discussed! in! the! enclosed!paper.!
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CD56+ monocytes have a dysregulated cytokine
response to lipopolysaccharide and accumulate in
rheumatoid arthritis and immunosenescence
Marco Krasselt, Christoph Baerwald, Ulf Wagner and Manuela Rossol*
Abstract
Introduction: Peripheral blood monocytes are no longer regarded as a homogeneous cell population, but can
be differentiated both phenotypically and functionally into various subpopulations. In rheumatoid arthritis, the
subpopulation of CD14bright/CD16+ monocyte is expanded and prone towards generation of Th17 cells. CD56+
monocytes represent a different subpopulation, which is also expanded in conditions associated with autoimmunity
like inflammatory bowel diseases. The aim of the study was the quantification and functional characterization of the
CD56+ monocyte subset in rheumatoid arthritis (RA).
Methods: Frequencies of peripheral blood monocyte subpopulations were analyzed by flow cytometry in 86
healthy controls and 75 RA patients. In 16 patients, anti-tumor necrosis factor (TNF) therapy was initiated, and the
CD56+ monocyte frequency was monitored longitudinally. Lipopolysaccharide (LPS)-induced cytokine production of
CD56+ and CD56– monocytes was determined by intracellular staining or cytokine secretion assays.
Results: In healthy individuals, 8.6% ± 0.6 of the monocytes co-expressed CD56, with the majority of CD56+
monocytes being CD14bright (7.9% ± 0.5), while only a minor population was CD14dim (0.7% ± 0.1). We found a
strong positive correlation between an individual’s age and the frequency of CD56+ monocytes. Upon stimulation
with LPS, CD56+ monocytes became more frequently positive for TNF, IL-10 and IL-23 than CD56– monocytes. In
addition, CD56+ monocytes spontaneously produced more reactive oxygen intermediates than CD56- monocytes.
In RA patients, the frequency of CD56+ monocytes was significantly higher than in healthy controls (12.2% ± 0.9 vs.
7.9% ± 0.5, p = 0.0002), and this difference most pronounced in RA patients below 40 years of age (11.1% ± 1.6 vs.
4.1% ± 0.4, P < 0.0001). Treatment of the patients with an anti-TNF blocking agent significantly reduced CD56+
monocyte frequencies (baseline 12.4% vs. 24 weeks treatment 8.0%, P = 0.0429), and the magnitude of this
decrease was found to correlate with the change in disease activity under the therapy.
Conclusion: The CD14bright/CD56+ monocyte subset is expanded in aging individuals as well as in patients with
RA. The pro-inflammatory production of cytokines and reactive oxygen species as well as the elimination of those
cells in patients with a good response towards TNF inhibiting agents indicates a possible contribution of those
monocytes in the inflammatory response in RA.
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Introduction
Peripheral blood monocytes are not a homogeneous cell
population, but represent different subpopulations with
distinct functions and cell surface markers. Three major
subpopulations can be distinguished by the expression
of the cell surface markers CD14 and CD16, classical
CD14brightCD16– monocytes, nonclassical CD14dimCD16+
monocytes and intermediate CD14brightCD16+ monocytes
[1]. More recently, a separate and less well-characterized
monocyte subpopulation has been described which is
characterized by the expression of the neural cell adhesion
molecule CD56 [2]. CD56+ monocytes are found in low
frequencies in the peripheral blood of healthy individuals
[2,3], patients with Down syndrome [4] and patients with
chronic myelomonocytic leukemia [5]. This monocyte
subpopulation is expanded in Crohn’s disease [3], pro-
duces typical monocyte cytokines [2] and is a more effi-
cient antigen-presenting cell population with regard to the
induction of a T-cell alloresponse [2].
It is already known that the monocyte compartment is
disturbed in patients with rheumatoid arthritis (RA). We
and others have observed an increase in the frequency of
CD16-expressing monocytes [6-8]. To date, no studies
evaluating the presence of CD56+ monocytes have been
performed in RA patients.
Herein we report an increased frequency of CD56+
monocytes in patients with RA compared to healthy
controls. The occurrence of CD56+ monocytes in the
peripheral blood is strongly age-dependent in healthy
controls, but this association is lost in RA patients.
CD56+ monocytes produce more tumor necrosis factor
(TNF), interleukin 10 (IL-10) and IL-23 than CD56–
monocytes, and anti-TNF therapy normalizes the fre-
quency of CD56+ monocytes in RA patients.
Methods
Human participants
Seventy-five patients with RA were included in the
study. The diagnosis of RA was based on the American
College of Rheumatology/European League Against
Rheumatism 2010 classification criteria for RA [9].
Sixteen patients required therapy with a TNF-blocking
agent because of their uncontrolled disease, and therefore
etanercept treatment was initiated while concomitant
disease-modifying antirheumatic drug therapy was contin-
ued. The dynamics of the CD56+ monocyte population
were monitored before the initiation of therapy and dur-
ing the following 24 weeks. The characteristics of the
study populations are shown in Table 1.
Eighty-six control subjects were recruited among heal-
thy blood donors (median age 53.5 years, range 22 to 72
years; 33 males and 53 females). The ethics committee
of the University of Leipzig approved all experiments
with human materials, and informed consent was
obtained from all participants.
Cell isolation and culture
Human peripheral blood mononuclear cells (PBMCs)
were isolated as described previously [10]. Cells were in-
cubated in RPMI 1640 medium supplemented with 10%
heat-inactivated fetal calf serum, 2 mM L-glutamine,
100 U/ml penicillin and 100 μg/ml streptomycin at a
concentration of 1 × 106/ml.
Flow cytometry
To identify monocyte subsets in the peripheral blood,
PBMCs were stained with anti-CD56-allophycocyanin
(AF12-7H3), anti-CD14-fluorescein isothiocyanate (TÜK4)
and anti-CD16-phycoerythrin (VEP13). Antibodies were
obtained from Miltenyi Biotec (Bergisch Gladbach,
Germany). Cells were analyzed using a FACSCalibur
flow cytometer and CellQuest software (BD Biosciences,
San Jose, CA, USA).






(N = 75) (N = 16)
Median age, years (range) 57.0 (23 to 83) 56.0 (41 to 66)
Female/male (n) 55/20 10/6
Median disease duration,
years (range)
7.0 (1 to 57) 2 (1 to 13)
RF-positive (%) 77.0 68.8
Anti-CCP-positive (%) 75.8 93.8






Anti-TNF + MTX 2 0
Abatacept 1 0
Hydroxychloroquine + MTX 1 1
Cyclosporin A 1 0




aCCP, cyclic citrullinated peptide; CRP, C-reactive protein; DMARDs,
disease-modifying antirheumatic drugs; MTX, methotrexate; RA, rheumatoid
arthritis; RF, rheumatoid factor; TNF, tumor necrosis factor.
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Measurement of cytokine production
PBMCs were stimulated for four hours (to measure TNF
production) or sixteen hours (to measure IL-10, IL-23
and IL-1β production) with 100 ng/ml ultrapure lipo-
polysaccharide (LPS) (InvivoGen, Toulouse, France) or
were left untreated. Subsequently, cells were harvested
and TNF-producing or IL-10-producing monocytes were
identified using cytokine secretion assays according to
the manufacturer’s protocol (Miltenyi Biotec). To deter-
mine IL-23 and IL-1β production, BD GolgiStop was
added and intracellular cytokine staining was performed
using BD Cytofix/Cytoperm Fixation/Permeabilization
Solution Kit (Becton Dickinson GmbH, Heidelberg,
Germany) and anti-IL-23 (eBioscience, San Diego, CA,
USA) or anti-IL-1β (R&D Systems, Minneapolis, MN,
USA) antibodies. Cells were analyzed using a FACSCalibur
flow cytometer and CellQuest software.
Reactive oxygen intermediate measurement
PBMCs were stimulated for up to two hours with 100
ng/ml ultrapure LPS or 20 ng/ml phorbol 12-myristate
13-acetate (PMA) or were left untreated. To detect re-
active oxygen intermediates (ROIs), dihydrorhodamine
123 was added to the living cells and fluorescence was
monitored using a FACSCalibur flow cytometer and
CellQuest software.
Statistical analysis
To determine statistical significance, Student’s t-test or
the Mann–Whitney rank-sum test was performed. Prior
to all comparisons, the Kolmogorov-Smirnov normality
test was done.
Results
Frequency of CD56+ monocytes increases throughout life
in healthy controls
CD56+ monocytes were identified in PBMCs by the co-
expression of CD56 and the monocytic surface marker
CD14 (Figure 1a). Eighty-six healthy controls were ana-
lyzed, and 8.6% ± 0.6 of the monocytes coexpressed
CD56. Most of the CD56+ monocytes are CD14bright
(7.9% ± 0.6), and only a minor population is CD14dim
(0.7% ± 0.1). Based on the scatter properties in flow
cytometric analyses, the CD14bright/CD56+ monocyte sub-
set had the appearance of classical monocytes, whereas
the CD14dim/CD56+ monocyte subset resembled large



























































































































Figure 1 CD14bright/CD56+ monocyte subset is expanded in older healthy controls and produces more cytokines in response to
lipopolysaccharide. (a) Representative dot plot of CD14 and CD56 expression on monocytes. Three relevant subpopulations are separated by
the quadrants and marked by the arrows in the right panel. APC, allophycocyanin; FITC, fluorescein isothiocyanate; FL1-H, fluorescence intensity
on channel that detects emissions from fluorescein isothiocyanate. (b) Scatterplot showing the correlation between age and the peripheral blood
frequencies of CD14bright/CD56+ monocytes in healthy controls. (c) Bar graphs depict the frequency of tumor necrosis factor-positive (TNF+)
(n = 5), interleukin 10-positive (IL-10+) (n = 8) and IL-23+ (n = 7) cells and the mean intracellular IL-1β content (n = 7) in CD56+ and
CD56– monocytes of healthy controls in response to lipopolysaccharide. (d) Spontaneous reactive oxygen intermediate (ROI) production
of CD56– and CD56+ monocytes (n = 4).
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lymphocytes and natural killer (NK) cells (data not
shown).
All subsequent analyses were performed on CD14bright/
CD56+ monocytes in comparison to CD14bright/CD56–
monocytes, unless stated otherwise.
It is already known that CD14bright monocytes can be
subdivided into two subpopulations by the expression
of the surface marker CD16 [1], representing classical
monocytes (CD14bright/CD16–) and intermediate mono-
cytes (CD14bright/CD16+). CD16 and CD56 expression
was coanalyzed in ten healthy controls. CD56+ mono-
cytes were found to be mostly CD16– and therefore to
belong to the classical CD14bright/CD16– monocytes.
Only 7.5% ± 1.6 of the CD56+ monocytes coexpressed
CD16 and belonged to the intermediate CD14bright/
CD16+ monocytes.
To analyze the influence of age on the CD56+ mono-
cyte subpopulation, the control cohort was recruited to
reflect a wide age range (median age 53.5 years, range 22
to 72 years). The analysis revealed a close positive
correlation between age and CD14bright/CD56+ mono-
cyte frequency (Figure 1b), as well as between age
and CD14dim/CD56+ monocyte frequency (r = 0.332,
P = 0.0018). No difference in CD56+ monocyte fre-
quencies between women and men were discernible
(data not shown).
CD14bright/CD56+ monocytes show an increased cytokine
production and spontaneous reactive oxygen
intermediate production
Little is known about the cytokine production of CD56+
monocytes. Sconocchia et al. performed a cytokine array
analysis [2], showing that CD56+ monocytes produce
typical monocytic cytokines, but no in vitro studies of
cytokine production of CD56+ monocytes in comparison
to CD56– monocytes have been performed.
A cytokine secretion analysis in monocytes of young
healthy controls revealed that increased frequencies of
cells producing the proinflammatory cytokines TNF and
IL-23 and the anti-inflammatory cytokine IL-10 in re-
sponse to LPS were found in CD14bright/CD56+ monocytes
compared to CD14bright/CD56– monocytes (Figure 1c). In
contrast, intracellular staining for IL-1β showed a similar
cytokine production of both CD14bright monocyte subsets
in response to LPS (Figure 1c). No difference in the
spontaneous production of cytokines was observed
(data not shown).
The production of ROIs in response to bacterial pro-
ducts is a characteristic feature of monocytes. No dif-
ference in LPS-induced ROI production was observed
between CD14bright/CD56+ monocytes and CD14bright/
CD56– monocytes (data not shown). The same result
was obtained when the production of ROIs was initiated
by direct stimulation of protein kinase C with PMA
(data not shown). However, the spontaneous production
of ROIs was higher in CD14bright/CD56+ monocytes
than in CD14bright/CD56– monocytes (Figure 1d).
Frequency of CD14bright/CD56+ monocytes is increased in
young rheumatoid arthritis patients
To analyze the CD56+ monocyte subpopulation in pa-
tients with RA, 75 patients with a median age of 57.0
years (range 23 to 83 years) were recruited. For a de-
tailed clinical description of the patient cohort, see
Table 1. Of the RA monocytes, 13.1% ± 0.9 coexpressed
CD56, 12.2% ± 0.9 were CD14bright and 0.9% ± 0.1 were
CD14dim.
In the global analysis, RA patients had a higher fre-
quency of CD14bright/CD56+ monocytes than healthy
controls (12.2% ± 0.9 vs. 7.9% ± 0.5; P = 0.0002). The
CD14dim/CD56+ monocyte subset was also found to
be expanded in RA patients (0.9% ± 0.1 vs. 0.7% ± 0.1;
P = 0.029), although the difference was less pronounced.
In view of the strong dependence of the CD56+ mono-
cyte frequency on age in the control cohort, the RA pa-
tients and controls were separated into three different
age subsets (20 to 39 years, 40 to 59 years and 60 years
and older). As shown in Figure 2a, the increase of
CD14bright/CD56+ monocyte frequencies in the RA pa-
tients was limited to the age subset from 20–39 years,
while frequencies in older RA patients did not differ sig-
nificantly from age-matched controls. The CD14dim/
CD56+ monocyte subset was also found to be expan-
ded in young RA patients (0.6% ± 0.1 vs. 0.8% ± 0.1,
p = 0.046) but not in older patients (data not shown).
In the global analysis of the total RA cohort, no cor-
relation of age with the CD14bright/CD56+ monocyte
subset was found (Figure 2b).
Analysis of the disease duration prior to study enroll-
ment revealed no correlation with the CD14bright/CD56+
monocyte frequency (data not shown). The CD14bright/
CD56+ monocyte subset is already expanded early in the
disease because RA patients with a disease duration of
one year have 12.0% ± 1.8 CD14bright/CD56+ monocytes
compared to 12.3% ± 1.1 CD14bright/CD56+ monocytes
in patients with a longer disease duration (P = n.s.). The
therapeutic regimen at the time of the analysis, the pres-
ence of rheumatic factor or anti-CCP antibodies, the ab-
solute monocyte count, C-reactive protein levels and
gender had no influence on CD14bright/CD56+ monocyte
frequency.
Therapeutic tumor necrosis factor blockade with
etanercept decreases frequency of CD14bright/CD56+
monocytes
To analyze the influence of treatment and of the the-
rapeutic response on the frequency of the expanded
CD14bright/CD56+ monocyte subset, the cell population
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was quantified in a longitudinally followed cohort of 16
RA patients before and during 24 weeks of treatment
with etanercept. Before the start of treatment, RA pa-
tients had a mean CD14bright/CD56+ monocyte frequency
of 12.4% ± 1.7, and no correlation of disease activity with
the frequency of CD14bright/CD56+ monocytes was de-
tectable (data not shown).
In the prospective analysis, the frequency of CD14bright/
CD56+ monocytes in this patient cohort was found to de-
crease after eight weeks of treatment and remained de-
creased for up to twenty-four weeks, which was the
endpoint of the study (Figure 3a). Interestingly, RA pa-
tients with a good response to the treatment also showed
a more pronounced decrease in the CD14bright/CD56+
monocyte frequency after 12 weeks (Figure 3b) and 24
weeks (data not shown) of treatment.
Discussion
To date, the CD56+ monocyte subpopulation has not
been very well-characterized. Although CD56+ mono-
cytes were found in 2001 in patients with Down syndrome
with or without an additional hematological disorder [4],
Sconocchia et al. first described CD56+ monocytes in the
peripheral blood of healthy controls in detail in 2005 [2].
However, the same study group had previously described
the differentiation of CD56+ monocytes from CD34+
stem cells in 2004 [11]. Herein we show that the frequency
of CD56+ monocytes dramatically increases with age in
healthy controls; that CD56+ monocytes produce more
TNF, IL-10 and IL-23; that CD56+ monocytes are ex-
panded in young RA patients; and that the CD56+
monocyte subset responds to anti-TNF treatment in
RA patients.
We were able to identify two subsets of CD14+ mono-
cytes coexpressing CD56 in the peripheral blood of
healthy controls and RA patients. The CD14bright/CD56+
monocyte subset represents the main CD56+ monocyte
population, and these cells had the same flow cytometry
scatter appearance as classical monocytes. In contrast, the
minor CD14dim/CD56+ monocyte subset mostly had the
appearance of lymphocytes and NK cells, which probably
corresponds to the CD56+ cell population described by
Gruenbacher et al. [12]. This group described CD56+ cells
in the peripheral blood, which are CD14dim, HLA-DR+
and CD86+; have the appearance of intermediate-sized
lymphocytes; and differentiate in vitro into dendritic cells.
Sconocchia et al. also described a CD56+/CD33+ myeloid
cell population which is able to differentiate in vitro into
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Figure 2 CD14bright/CD56+ monocyte subset is expanded in young rheumatoid arthritis patients. (a) Peripheral blood frequencies of
CD14bright/CD56+ monocytes in healthy controls (HD) and rheumatoid arthritis patients (RA). (b) Correlation between age and the peripheral
blood frequencies of CD14bright/CD56+ monocytes in RA patients.
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cells with a dendritic cell morphology [13]. Although the
two CD14bright/CD56+ and CD14dim/CD56+ populations
have different size and granularity proportions, it remains
to be established whether these populations are truly two
different monocyte subsets or if they belong to one
CD56+ monocyte subset. Some of our observations point
to the latter possibility because both CD14bright/CD56+
and CD14dim/CD56+ populations increase comparably
with age in healthy controls and are equally expanded in
RA patients.
We observed only a minimal overlap of the CD14bright/
CD56+ monocyte subset with the well-characterized
CD14bright/CD16+ intermediate monocyte subset (7.5% of
the CD56+ monocytes coexpressed CD16). Contamina-
tion with NK cells can be excluded because the cells
expressed high levels of the monocytic lineage marker
CD14. CD14bright/CD16+ intermediate monocytes are the
main producer of IL-1β, TNF and IL-23 in response to
LPS [14]; are expanded in RA patients [6]; and promote
the expansion of Th17 cells [6]. Most of the CD14bright/
CD56+ monocytes belong to the classical CD14bright/
CD16– monocyte subset, which is the main producer of
ROIs, CCL2 and IL-8 in response to LPS [14]. In our
study, we demonstrated that CD14bright/CD56+ mono-
cytes produce more of the typical monocyte cytokines
TNF, IL-10 and IL-23 in response to LPS than CD14bright/
CD56– monocytes do. This cytokine response to LPS clas-
sifies the CD14bright/CD56+ monocytes into the inflam-
matory subset described by Cros et al., contrary to the
patrolling monocytes which respond to viruses and nu-
cleic acids, but only weakly to LPS [14].
One major finding of the present study is the strong
expansion of the CD14bright/CD56+ monocyte subset
with increasing age in healthy controls. The aging pro-
cess is associated with age-related changes in the im-
mune system, a phenomenon called immunosenescence
[15,16]. In RA, characteristic signs of immunosenescence
are present in the adaptive immune system, in particular
in the T-cell compartment [17]. However, immunosene-
scence can also be observed in the innate immune sys-
tem [18]. Monocytic cells of aged mice produce lower
amounts of cytokines in response to Toll-like receptor
activation [19,20], but older mice have increased cyto-
kine levels in in vivo models of sepsis [21,22]. The influ-
ence of age on LPS-induced human monocyte cytokine
production has been a subject of controversy, with re-
ports ranging from increased to decreased cytokine
production [23-26]. In our study, the CD14bright/CD56+
monocytes produced more cytokines in response LPS and
spontaneously released more ROIs than classical mono-
cytes, but more comprehensive analyses in older people
are needed.
Conflicting results have been reported regarding the
influence of age on absolute monocyte numbers in the
peripheral blood [27,28] and the CD16 monocyte subset
composition [23,28,29]. In a previous study of the
CD14bright/CD16+ monocyte subset in patients with RA,
however, we did not observe an age-dependent increase
in the CD16+ monocyte subsets in healthy controls and
RA patients [6]. In the present study, we observed an in-
crease in the CD14bright/CD56+ monocyte subset from
4.7% in healthy controls younger than 30 years of age to
10.2% in healthy controls older than 60 years of age. The
CD14bright/CD56+ monocyte subset in RA is expanded
in younger patients, probably reflecting a preaged innate
immune system in RA patients.
In RA, the monocyte subset is dysregulated. In com-
parison to healthy controls, the absolute number of all
monocyte subsets is increased [7,30], and, in relation to
the other CD16-defined monocyte subsets, the CD14bright/
CD16+ monocyte subset is also expanded [6]. Herein we





































Figure 3 CD14bright/CD56+ monocyte subset decreases during
therapeutic tumor necrosis factor blockade. (a) Peripheral blood
frequencies of CD14bright/CD56+ monocytes in 16 RA patients
before and after treatment with etanercept. (b) Change in Disease
Activity Score in 28 joints (∆DAS28) and CD14bright/CD56+ monocyte
frequency at week 12 of treatment with etanercept (Enbrel)
correlated to baseline (n = 16).
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describe another monocyte subpopulation, CD14bright/
CD56+ monocytes, which is expanded in RA patients.
Considering that the CD14bright/CD56+ monocyte subset
only minimally overlaps the CD14bright/CD16+ monocyte
subset, RA patients have a major shift toward pathological
monocyte subpopulations at the expense of classical
monocytes. The expansion of the CD14bright/CD56+ mo-
nocyte subset in RA patients was not associated with the
inflammatory state of the patients, but we did observe a
reduction of the subpopulation during anti-TNF treat-
ment. This decrease in the CD14bright/CD56+ monocyte
frequency was also associated with a better response to
the treatment.
Conclusion
The CD14bright/CD56+ monocyte subset is present in
healthy controls and expands with increasing age. The
frequency of CD14bright/CD56+ monocytes is increased
in RA patients, declines with effective anti-TNF treat-
ment and is associated with a better response to treat-
ment. CD14bright/CD56+ monocytes produce increased
cytokine levels in response to LPS and have higher spon-
taneous ROI production. The CD14bright/CD56+ mono-
cyte subset might therefore represent monocytes from a
preaged immune system with dysregulated cytokine and
ROI production, but further studies are required to con-
firm this hypothesis.
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!eingereicht!von:! ! Marco!Lothar!Krasselt!angefertigt!am!/!in:! 3.!Februar!2014,!Universitätsklinikum!Leipzig!betreut!von:!! ! Prof.!Dr.!med.!Ulf!Wagner,!Dr.!rer.!nat.!Manuela!Rossol!Monat!und!Jahr:! ! Februar!2014!!!IV.! Summary!!Peripheral!blood!monocytes!are!no! longer!regarded!as!a!homogeneous!cell!population,!but!can! be! differentiated! into! various! subpopulations.! In! the! present! study,! CD14bright/CD56+!monocytes,! an! only! recently! identified! and! poorly! examined! subpopulation,! was! further!investigated.! This! population! had! been! described! before,! but! the! current! investigations!yielded!the!following!new!findings:!1. a!higher!frequency!of!those!cells!among!patients!suffering!from!Rheumatoid!Arthritis!(RA),!especially!in!young!patients!below!the!age!of!40,!2. a!strong!positive!correlation!of!the!frequency!of!this!subpopulation!with!the!age!of!the!healthy!controls,!3. an! increased! cytokine! and! reactive! oxygen! intermediate! (ROI)! production! ! of!CD14bright/CD56+!monocytes!compared!to!classical!monocytes!and!4. a!reduction!of!those!cells!during!effective!TNFαFblocking!treatment.!This!findings!are!of!great!interest!and!implicate!these!cells!in!the!complicated!pathogenesis!!of!RA,!but!also!in!immunosenscence.!!
&
&
! !! ! 31!
Flow&Cytometry&Results&
Healthy$controls$Overall!86!healthy!donors!(22F72!years!old,!53.5!years!in!median)!were!included!and!blood!samples!have!been!processed!for!flow!cytometry,!in!order!to!stain!PBMCs!for!the!fluorescent!markers! of! interest! (antiFCD56FAPC,! antiFCD14FFITC! and! antiFCD16FPE).! CD56+!monocytes!were! identified! in!PBMCs!by! the!coFexpression!of!CD56!and! the!monocytic! surface!marker!CD14.! Based! on! the! scatter! properties! in! flow! cytometric! analyses,! the! CD14bright/CD56+!monocyte!subset!had!the!appearance!of!classical!monocytes;!the!CD14dim/CD56+!ones!rather!resemble! lymphocytes! and! NKCs.! Most! of! the! cells! of! our! interest! belong! to! the! typical!CD14bright/CD16F!monocyte!subset.!Results!showed!a!strong!positive!correlation!of!CD14bright/CD56+!monocytes!and!the!donor’s!age!(r=0.563;!p!<!0.0001)!without!any!differences!between!men!and!women.!
RA$patients$Overall! 75! RA! patients! (23F83! years! old,! 57! years! in! median)! were! included! and! blood!samples! have! been! processed! just! like! for! the! healthy! donors.! Results! showed! a! higher!frequency!of!CD14bright/CD56+!monocytes!in!patients!than!in!healthy!controls!(12.2!%!±!0.9!vs.!7.9!%!±!0.5;!p=0.0002)!with!no!age!correlation!at!all.!When!dividing!all!donors,!patients!and!controls,!into!three!ageFmatched!groups!(20F39!yrs.,!40F59!yrs.,!60!yrs.!and!above),!the!increased!frequency!favouring!the!patients!only!was!to!be!found!within!the!youngest!group!(20F39!yrs.)!while!not!seeing!any!significant!differences!at!the!age!of!40!and!above.!!
Cytokine&Production&and&Reactive&Oxygen&Intermediate&Measurement&Investigations!further!revealed!CD14bright/CD56+!monocytes!showing!an!increased!cytokine!production!on!stimulation!with!ultrapure! lipopolysaccharide! (LPS)!as!well!as!an! increased!spontaneous! reactive! oxygen! intermediate! (ROI)! production.! All! analyses!were! performed!on! monocytes! of! healthy! controls! using! cytokine! secretion! assays,! intracellular! cytokine!staining!or!dihydrorhodamine!123Fbased!ROIFmeasurement!respectively.!
Cytokine$production$The! significantly! increased! amount! of! cells! producing! cytokines! on! LPSFstimulation! was!found!for!the!proFinflammatory!cytokines!TNFα!and!ILF23;!the!frequency!was!increased!for!ILF10!as!well.!There!was!no!significant!difference!in!ILF1β!production.!
ROI$production$Contrary,!when!examining!ROI!production,!no!difference!after!LPS!or!PMA!stimulation!was!found! while! the! spontaneous! production! was! significantly! increased! in! CD14bright/CD56+!monocytes.!
&
&
! !! ! 32!
Longitudinal&Etanercept&Study&To!analyze!the!influence!of!treatment!and!the!therapeutic!response!on!the!frequency!of!the!expanded! CD14bright/CD56+! monocyte! subset,! the! cell! population! was! measured! in! a!longitudinally,!prospective!treatment!study!using!Etanercept.!The!cohort!consisted!of!16!RA!patients.!The!median!amount!of!the!CD14bright/CD56+!monocyte!subset!decreased!significantly!during!the!therapy!with!Etanercept!after!8!weeks!and!remained!low!for!the!whole!study!duration!of!24!weeks.!Additionally!and!clinically!very! important,! the!decrease! in!CD14bright/CD56+!cells!went! along!with! a! good! treatment! response!measured!by! the! clinical!widely! used!Disease!Activity!Score!28!(DAS28).!!
Conclusion&The! results! of! the! study! presented! in! the! published! manuscript! are! promising! and! very!interesting! when! trying! to! understand! the! pathogenesis! of! RA.! The! described!CD14bright/CD56+! monocyte! subset! is! not! only! positively! correlated! with! age! in! healthy!controls!but!also!seems!to!be!increased!in!young!patients!suffering!from!RA.!These!findings!alone!are!leading!to!the!assumption,!that!there!might!be!a!connection!to!immunosenescence,!possibly!with!relevance!for!the!development!of!RA.!The!aging!of!the!human!immune!system!was!described!and!investigated!before,!more!widely!for!the!adaptive,!but!also!for!the!innate!immunity.!Results!remain!conflicting!so!far,!but!there!is! consensus! about! an! inflammatory! condition,! called! “inflameFaging”! in! older! people! as!being!illustrated!by!elevated!cytokine!levels.!Especially! the! ageFdependent! response! of! monocytes! to! LPSFactivation! is! discussed!controversially,!with!results!ranging!from!decreased!to! increased!cytokine!production.!The!results! at! hand! show! an! increased! production! of! proFinflammatory! cytokines! within! the!investigated!subpopulation,!supporting!the!assumed!immunosenescent!state! in! the!elderly.!This! assumption! is! emphazised!by! the! fact,! that! spontaneous!ROI!production!occurs!more!frequently.! It! seems! that! RA! patients! are! having! a! disturbed! monocyte! panel! with! an!increased!amount!of!proFinflammatory!monocytes!at!the!expense!of!classical!monocytes.!Moreover,! the! frequency!of! the! examined! subpopulation! in!peripheral!blood!declines!with!effective! TNFαFblocking! treatment! and! this! decline! is! associated! with! a! better! therapy!response.!When!summing!up!all!those!findings,!the!identified!monocyte!subset!might!represent!cells!of!a!prematurely!aged!immune!system!with!a!dysregulated!cytokine!production!pattern!and!an!increased!spontaneous!ROI!production,!which!are!probably!involved!in!the!pathogenesis!of!Rheumatoid!Arthritis.!Additional!investigations!are!needed!to!confirm!those!hypotheses.!!
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V.! Enclosures!
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V.1& Abbreviations&&
&ACPA! !!! ! AntiFcitrullinated!Proteins/Peptides!Antibodies!APC!(I)!![FACS]!! Allophycocyanin!APC!(II)! ! Antigene!Presenting!Cell!BCR! ! ! B!cell!Receptor!CD! ! ! Cluster!of!Differentiation!CR!! ! ! Complement!Receptor!DAS!! ! ! Disease!Activity!Score!FACS! ! ! FluorescenceFactivated!Cell!Sorting!FITC! ! ! Fluorescein!Isothiocyanate!FoxP3! ! ! ForkheadFBoxFProtein!P3!HLA!! ! ! Human!Leucocyte!Antigen!IFNγ!! ! ! Interferon!γ!IL! ! ! Interleukin!LPS!! ! ! Lipopolysaccharide!NADPH!! ! Nicotinamide!Adenine!Dinucleotide!Phosphate!NCAM! !! ! Neural!Cell!Adhesion!Molecule!NFFκB!! ! ! Nuclear!Factor!'kappaFlightFchainFenhancer'!of!Activated!BFcells!NKC!! ! ! Natural!Killer!Cell!PADI!! ! ! Peptidylarginine!Deiminase!PBMC! !! ! Peripheral!Blood!Mononucleated!Cell!PE! ! ! Phycoerythrin!PMA! ! ! PhorbolF12FmyristatF13Facetat!PMN!! ! ! Polymorphonuclear!Neutrophil!PTPN22!! ! Protein!Tyrosine!Phosphatase,!NonFReceptor!type!22!RA!! ! ! Rheumatoid!Arthritis!RF!! ! ! Rheumatoid!Factors!ROI!! ! ! Reactive!Oxygen!Intermediate!RR! ! ! Relative!Risk!SE!! ! ! Shared!Epitope!SNP!! ! ! Single!Nucleotide!Polymorphism!TCR!! ! ! T!cell!Receptor!TGFβ! !! ! Transforming!Growth!Factor!β!TLR! ! ! TollFlike!Receptor!TNFα! !! ! Tumor!Necrosis!Factor!α!
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V.2& Eigenständigkeitserklärung!
&Hiermit!erkläre! ich,!dass! ich!die!vorliegende!Arbeit!selbständig!und!ohne!unzulässige!Hilfe!oder!Benutzung!anderer!als!der!angegebenen!Hilfsmittel!angefertigt!habe.!Ich!versichere,!dass!Dritte!von!mir!weder!unmittelbar!noch!mittelbar!geldwerte!Leistungen!für! Arbeiten! erhalten! haben,! die! im! Zusammenhang! mit! dem! Inhalt! der! vorgelegten!Dissertation! stehen,! und! dass! die! vorgelegte! Arbeit! weder! im! Inland! noch! im! Ausland! in!gleicher!oder!ähnlicher!Form!einer!anderen!Prüfungsbehörde!zum!Zwecke!einer!Promotion!oder!eines!anderen!Prüfungsverfahrens!vorgelegt!wurde.!Alles!aus!anderen!Quellen!und!von!anderen!Personen!übernommene!Material,!das!in!der!Arbeit!verwendet!wurde!oder!auf!das!direkt!Bezug!genommen!wird,!wurde!als! solches!kenntlich!gemacht.! Insbesondere!wurden!alle!Personen!genannt,!die!direkt!an!der!Entstehung!der!vorliegenden!Arbeit!beteiligt!waren.!!!!!...........................................................! ! ! ...........................................................!Ort,!Datum! ! ! ! ! M.!L.!Krasselt!
&
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V.3& Curriculum&Vitae&
&
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V.4& Publications&
&
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V.5& Closing&Words&
&This!thesis! is!dedicated!to!my!marvelous!mother!Andrea!(1962F1998)!who!left!way!before!her!time.!You!made!me!become!a!physician!and!a!better!person.!Completing!it!was!only!possible!due!to!the!awesome!support!of!my!loving!family,!especially!my! beloved! Julia,!my!wonderful! sister! Katrin! and!my! great! father! Gunther.! It! is! you! guys!overwhelming!me!with!gratitude!for!your!help.!I!honestly!thank!you!for!always!being!there!and!never!stopping!to!believe!in!me.!I! also! sincerely! thank! Dr.! Manuela! Rossol! and! Prof.! Dr.! Ulf! Wagner! for! giving! me! the!oppurtunity!to!do!this!work!using!their!lab!and!beginning!to!research!on!those!huge!and!very!interesting! field! of! science.! It! has! been! a! great! pleasure! to!work!with! you! both;! you! have!always! had! an! opened! ear! for! me! and,! more! important,! I! could! count! on! your! personal!support!as!well!as!your!scientific!expertise!anytime.!Last!but!not!least!I!want!to!thank!the!Medical!Faculty!of!the!University!of!Leipzig!for!granting!the!urgently!needed!scholarship!for!this!work!when!I!still!was!attending!medical!school.!!!!!!!!!!!!!!!! !!!!People!are!always!blaming!their!circumstances!for!what!they!are.!I!don’t!believe!in!circumstances.!The!people!who!get!on!in!this!world!are!the!people!who!get!up!and!look!for!the!circumstances!they!want,!and,!if!they!can’t!find!them,!make!them.!
George!Bernhard!Shaw!
